Skip to main content

Market Overview

One Thing You Should Note About Molina's Q1 Earnings Per Share Figure

Share:
One Thing You Should Note About Molina's Q1 Earnings Per Share Figure

Molina Healthcare, Inc. (NYSE: MOH) announced first-quarter results Tuesday following an earlier announcement concerning the ouster of its CEO and chief financial officer, both sons of the healthcare company's founder.

The 'Adjusted, Adjusted' Earnings

Stifel in a note looked at what it termed as the "adjusted, adjusted" first-quarter measure. Analysts Thomas Carroll and Mark Kelly clarified the adjusted earnings per share of $1.47 Molina reported for the first quarter was not adjusted for the one-time benefit from the Humana Inc (NYSE: HUM) termination fee of $0.84 per share.

Accordingly, the analysts viewed the adjusted earnings per share as $0.63, which is ahead of the $0.58 per share consensus estimate. The analysts said the earnings suggest the business has not continued to deteriorate from prior expectations provided on the fourth quarter.

Guidance Essentially Unchanged

The analysts noted the company essentially reiterated its 2017 earnings per share guidance of $2.09, which was adjusted higher to include the Humana payment and communicated as $2.90.

"In our view, this measure is not the appropriate point to consider 2018 and beyond," the analysts said.

Stifel raised its 2017 earnings per share estimate to $2.09 from $1.95 and 2018 estimate to $3.10 from $3, although clarifying it has little confidence in this estimate.

"In light of many uncertainties with the MOH business along with the change in leadership, we are moving our estimate to guidance and will work to establish a forecast with better confidence," the firm said to clarify the upward adjustment.

Remaining At Hold

Stifel said it does not see shares of the company doubling in the foreseeable future, given many uncertainties. The firm maintains its Hold rating and $47 price target for the shares of Molina.

Related Links:

Deutsche Initiates Coverage On Health Stocks As National Health Insurance Debate Rages On

Companies That Have The Most To Lose If Obamacare Is Repealed

Latest Ratings for HUM

DateFirmActionFromTo
Mar 2022Morgan StanleyMaintainsEqual-Weight
Feb 2022SVB LeerinkMaintainsOutperform
Jan 2022Wells FargoMaintainsOverweight

View More Analyst Ratings for HUM

View the Latest Analyst Ratings

 

Related Articles (HUM + MOH)

View Comments and Join the Discussion!

Posted-In: Analyst Color Earnings News Guidance Health Care Reiteration Management Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com